Smaller companies bear the burden of not having connections to resources and services that larger companies may have access to due to their prominent reputation in the industry. In this case it is crucial that the smaller companies have a thorough management system set in place so that all their needs and expectations are met. Unfortunately smaller companies have a higher chance of getting the short end of the stick in these situations due to their lack of power in the industry. To help mitigate any chances of the company from not getting what they wanted they should have a strong open line of communication with the clinical trial management company. Prior to any work starting, all expectations, customer needs, and requirements need to be outlined and agreed upon by both parties. Additionally, there needs to be a verification protocol set in place so that the smaller company (the client) is getting what they asked for and has a chance to express concerns/dissatisfaction in between trials. Lastly, both parties need to regularly review whether the project is on track as expected to help ensure that the given task is completed as requested.

As @ag2265 mentioned above, to maintain a successful collaboration between a small company and an external clinical trial team, it is important that company representatives emphasize strong and friendly communication from the start of the clinical trial. To add, it’s important that both the clinical trial team and company representatives sit together to develop an experimental protocol that targets the company’s needs. Along with maintaining regularly scheduled meetings to discuss study design and results, I also think it’s important for a company representative to be present at all clinical trial experiments. Having a company representative present at experiments not only ensures that the protocol is followed for desired outcomes, but also that the product being tested is being handled correctly. If a product is handled incorrectly, the outcomes of a clinical trial are not reliable. To conclude, although a small company may not be able to perform clinical trials on their own, a project team still needs to work closely with external clinical trial management teams to ensure that the correct work is being done. Some projects run clinical trials at several external locations. Are there any additional steps that need to be taken to ensure that more than one clinical trial management team is following a contract correctly?

Smaller businesses should carefully analyze and manage the contract they get into with a firm that specializes in clinical trial management to make sure the terms and circumstances are advantageous and match their needs. The following actions can be taken by smaller businesses to efficiently analyze and manage the contract:

• Know the services being provided: Smaller businesses should make sure the contract outlines the specific services the clinical trial management company will be providing. This covers the schedule, spending plan, and any deliverables.
• The performance of the clinical trial management organization should be measured using key performance indicators (KPIs), which smaller businesses should define. This will ensure that the business achieves the goals and benchmarks set.
• Negotiate the terms: Smaller businesses should bargain the contract's terms to ensure that they are advantageous and that they are safeguarded against any potential problems. This covers the payment conditions, cancellation policies, who owns the intellectual property, and liabilities.
• Smaller businesses should keep an eye on the clinical trial management company's performance throughout the duration of the contract. This entails maintaining regular contact and gatherings, going through status updates, and evaluating the caliber of the work.
• Describe any problems: Smaller organizations should speak with the clinical trial management company as soon as any problems develop during the term of the contract. This covers any performance problems, delays, or modifications to the project's scope.

Assuming that once a smaller companies has identified a suitable clinical trial management company to contract with, payment could become a key part in managing the contract between the two companies. With smaller companies, monetary resources may not be so freely available. The question could become whether the company would like a lump-sum payment, or a tiered-payment agreement which covers parts of the clinical trial as they come. This may seem like a rather minor detail in the grand scheme of clinical trials, however it ensures that the clinical trial company assumes some risk as their own. Without "guaranteeing" payments for the entire clinical trials, the sponsoring company may agree to release payment during scheduled meetings to evaluate whether deliverables were completed with integrity and to the specifications provided by the sponsor. This can work both ways where unpleasable results could lead to a dispute over payment. To avoid this, a comprehensive contract can be made in which both companies assume a somewhat equal risk during the clinical trials.

For smaller companies without their own clinical trial management departments, it is important to ensure that they have the proper structure in place to maintain oversight of the CROs and their work on behalf of the sponsor or smaller company. This means having established governance measures in the contract that govern the sponsor’s relationship with the CRO, such as a clearly defined scope of work and metrics for performance. Even though smaller companies often do not have extensive internal expertise, they can maintain control through ongoing routine status reviews, audit rights, independent consultants, and periodic risk assessments to ensure the CRO is meeting expectations. Thus, contract management is not so much about specifying every detail of how the operational aspect of the work performed by a CRO will be accomplished, but more about establishing and creating a structured oversight process with multiple points of decision where the sponsor remains in control.

I also think vendor selection is part of managing the contract before the trial even begins. Due diligence on a CRO’s track record, therapeutic expertise, and quality systems may be just as important as managing performance after launch. A smaller company may rely heavily on its partner's expertise, therefore, it is essential to have clear communication, escalation procedures, and milestone-linked payments for both parties to maintain accountability. The act of outsourcing clinical trials does not eliminate the management of the trial; rather, it moves that management responsibility from the direct execution of the clinical trial by the sponsor onto the sponsor's supervision or oversight and the relationship management with the CRO. That raises an interesting question: for smaller companies with limited experience, is it better to invest early in outside consultants to strengthen sponsor oversight, or can overreliance on external advisors create its own risks and inefficiencies?

Reading through the replies, there are several very good points and insight offered for how a smaller/less experienced company would handle this kind of situation. One suggestion I didn't see mentioned but is crucial is this: hiring the right people. Its simple, if you're a small organization growing into the business, and you know that you'll be encountering this kind of work regularly, you need to hire the right people that will help elevate you to a safe position that you can handle and negotiate from comfortably in the market. Your niche isn't your company's reputation, it isn't money. But it can be having the right people that will understand and know what's needed from the company that you're contracting to perform and/or manage your clinical trials. This will level the playing field. Understanding well what's needed for clinical trials, in conjunction with following ISO guidelines will allow your smaller company to successfully continue competing in industry as it grows. 

One idea I haven’t seen mentioned yet is the importance of building internal minimal oversight expertise even if the company outsources everything else. A smaller company might not have a full clinical trial team, but having at least one person who understands trial design, regulatory expectations, and CRO workflows can make a big difference in how the contract is managed. Without that internal knowledge, it’s hard to know if the CRO is actually performing well or just meeting surface-level deliverables. Even things like timelines, protocol deviations, or data quality issues can go unnoticed if no one internally knows what to look for. So instead of relying entirely on the CRO, the company should invest in just enough internal expertise to ask the right questions and challenge decisions when needed. I also think this reduces risk long-term. Even if the CRO is doing most of the work, the responsibility still ultimately sits with the sponsor company. Having internal oversight capability helps ensure the company stays accountable and doesn’t lose control of the trial just because it was outsourced.